CIAS
ALNY icon

Capital Investment Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capital Investment Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-333
Closed -$27K – 572
2019
Q3 		$27K Hold
333
– – 0.01% 720
2019
Q2 		$25K Buy
+333
New +$25.5K 0.01% 722

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital Investment Advisory Services's ALNY Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2019, closing a stake of 333 shares — an estimated $27K sold.

Capital Investment Advisory Services first reported a position in ALNY in Q2 2019 and held it in 2 quarters. The position peaked at $27K in Q3 2019. 315 funds tracked by Wall St. Rank hold ALNY as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining Alnylam Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 333 Alnylam Pharmaceuticals shares in Q4 2019, an estimated $27K.
  • Capital Investment Advisory Services first reported a position in Alnylam Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Capital Investment Advisory Services's Alnylam Pharmaceuticals position peaked at $27K in Q3 2019.
  • 315 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.